What question did this study set out to answer?

To investigate the impact of GLP-1 receptor agonists on the risk of thyroid eye disease.

April 10, 2026

Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Thyroid Eye Disease

Key Points

To investigate the impact of GLP-1 receptor agonists on the risk of thyroid eye disease.
Matched cohort analysis
Comparison of GLP-1RA therapy to other glucose-lowering medications
Assessment of TED diagnoses, surgeries, and steroid use
GLP-1RA therapy associated with reduced risk of TED diagnoses
Lower rates of TED-related surgeries in patients using GLP-1RAs
Decreased systemic steroid use linked to GLP-1RA therapy

Abstract

In a large, rigorously matched cohort, GLP-1RA therapy was associated with a reduced risk of TED diagnoses, surgeries, and systemic steroid use compared to other glucose-lowering medications. These findings suggest a potential protective role for GLP-1 signaling in modulating orbital inflammation, though prospective trials are required for confirmation.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Jawad Muayad

Muhammad Z. Chauhan

University of Arkansas for Medical Sciences

Leo M. Hall

Journals

Ophthalmic Plastic and Reconstructive Surgery

Actions

Institutions

Cornell University

University of Toronto

The University of Texas MD Anderson Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Thyroid Eye Disease

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider